IMM01, developed internally by ImmuneOnco, is a novel proprietary immunotherapeutic molecule. IMM01 works by inhibiting CD47 and potently promoting antibody-dependent cellular phagocytosis (ADCP); it activates macrophages to engulf tumor cells and present tumor antigens to T cells, thus directing potent immune responses against tumor cells. Further, IMM01 does not bind human red blood cells, which is a common side effect of other anti-CD47 compounds.
IMM2902, a novel proprietary bispecific targeting CD47 and HER2, was designed based on ImmuneOnco’s “mAb- Trap” platform technology. The HER2 antibody portion of IMM2902 inhibits tumor growth by accelerating HER2 endocytosis and degradation; while the “Trap” (modified SIRPa) portion if IMM2902 inhibits “don’t eat me” signal and activates “eat me” signal from tumor cells, activates macrophages to engulf tumor cells and present tumor antigens to T cells, thus directing potent immune responses against tumor cells. Main indications of IMM2902 include HER2 positive breast cancer, stomach cancer, lung cancer and other solid tumors.
IMM0306 is our proprietary mAb-Trap fusion protein that simultaneously targets CD47 and CD20 and a potentially First-in-Class therapeutic compound. It targets both tumor marker CD20 and SIRPa-CD47 immune pathway, by activating macrophages and natural killer cells for potent antitumor effects.